Importance
Despite the integration of bevacizumab and poly(ADP-ribose) polymerase inhibitors into first-line treatment of advanced high-grade serous ovarian cancer, survival remains poor for the substantial subset of patients whose tumors respond insufficiently to platinum-based chemotherapy and who, therefore, frequen...
Benoît You, A. Clamp, K. Moore et al.· JAMA Oncology· 0 citations
Gynecological malignancies remain a major cause of cancer-related morbidity and mortality, particularly in recurrent and treatment-resistant settings. Advances in molecular profiling have accelerated the development of biomarker-driven therapies, expanding treatment options beyond conventional chemotherapy and first-ge...
K. Ouali, Dsp Tan, S. Lheureux et al.· Annals of Oncology· 0 citations
CD8 T-cell populations showed the strongest methodological concordance, establishing their priority as a robust candidate biomarker for immune activation to be used in further clinical research.
C. Gaspar, Benson Z. Wu, Simone C. Stone et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.